Stereotactic Body Therapy for Urologic Cancers
Author Information
Author(s): Coles-Black Jasamine, Rahman Adib, Siva Shankar, Ischia Joseph, Perera Marlon, Bolton Damien, Lawrentschuk Nathan
Primary Institution: The University of Melbourne
Hypothesis
The aim of this narrative review is to provide an overview on the current landscape of SABR in urologic cancers and highlight advancements on the horizon.
Conclusion
SABR has emerged as a safe, effective, and feasible treatment for urologic cancers.
Supporting Evidence
- SABR resulted in excellent tumour control with a 95.3% 5-year biochemical recurrence-free survival.
- Increasing the SABR dose was associated with improved biochemical control.
- SABR has a low toxicity profile when used for metastatic prostate cancer.
- SABR offers adequate local control with a modest impact on renal function in patients unfit for surgical management.
- SABR has been shown to be superior to conventional radiotherapy for metastatic RCC.
Takeaway
SABR is a special type of radiation therapy that helps treat prostate and kidney cancers safely and effectively.
Methodology
A narrative review of the contemporary role of SABR in urologic cancers is conducted.
Potential Biases
The study suggested that the discrepancy between acute toxicity of SABR in different trials may be due to variations in treatment techniques.
Limitations
Most studies to date constitute phase I-II trials and single-centre studies.
Participant Demographics
The study included 6116 men with localised prostate cancer across 36 prospective studies.
Statistical Information
P-Value
p < 0.001
Confidence Interval
95% CI, 91.3–97.5%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website